Kolon TissueGene, Inc. (KOSDAQ:950160)
South Korea · Delayed Price · Currency is KRW 13,900
-20 (-0.14%)
Nov 2, 2026, 3:30 PM KST
Kolon TissueGene Market Cap
Kolon TissueGene has a market cap or net worth of 1.18 trillion as of October 30, 2026. It is the 10,459th most valuable company in the world and the 263rd biggest in South Korea. Its market cap has decreased by 68.32% in one year.
Market Cap
1.18T
Enterprise Value
1.15T
Revenue
4.80B
Global Rank
Country Rank
#263 South Korea
PE Ratio
n/a
ChartMarket Cap Chart
Since November 6, 2017, Kolon TissueGene's market cap has decreased from 2.58T to 1.18T, a decrease of -54.19%. That is a compound annual growth rate of -8.31%.
| Date | Market Cap | % Change |
|---|---|---|
| Nov 2, 2026 | 1.18T | -82.17% |
| Dec 30, 2025 | 6.62T | 258.54% |
| Dec 30, 2024 | 1.85T | 181.73% |
| Dec 28, 2023 | 655.80B | 7.08% |
| Dec 29, 2022 | 612.43B | -76.74% |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2017 | Upgrade Pro | Upgrade Pro |
| Nov 6, 2017 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| LigaChem Biosciences | 2.27T |
| ABL Bio | 2.19T |
| Peptron | 2.15T |
| OliX Pharmaceuticals | 2.14T |
| Hugel | 1.94T |
| Voronoi | 1.92T |
| D&D Pharmatech | 1.87T |
| Komipharm International | 651.95B |